Researchers at the University of California, Berkeley, have identified an experimental compound that helped obese mice burn more energy, improve blood sugar control and lose fat while largely preserving lean muscle. Unlike GLP-1 drugs such as Ozempic and Wegovy, which primarily reduce appetite and food intake, the compound—5-tetradecyloxy-2-furoic acid, or TOFA—targets energy expenditure. It increased energy use by as much as 18% in mice without making them more active or raising their body temperature, and it enhanced the effects of several existing weight-loss drugs. However, TOFA has not yet been shown to be safe or effective in humans.
A different approach to weight loss
Over the past five years, GLP-1-based medicines have transformed the treatment of obesity and metabolic diseases, including diabetes and fatty liver disease. Drugs sold as Ozempic, Wegovy, Mounjaro and Zepbound have helped many patients lose substantial weight while improving blood sugar regulation.
These medicines also have limitations. Nausea and other digestive problems can make treatment difficult for some people. Because they reduce appetite and food intake, they may also increase the risk of nutritional deficiencies and loss of muscle mass. Excessive muscle loss over time can contribute to weakness and other health complications.
The Berkeley researchers investigated a fundamentally different strategy: increasing the amount of energy the body burns rather than relying primarily on reduced calorie intake.
Energy expenditure includes the calories used to maintain basic bodily functions, regulate metabolism and support daily activities. Increasing it could help people lose weight without depending solely on eating less.
“Weight responds to two levers: eating fewer calories or expending more energy,” said Anders Naar, a professor of metabolic biology and nutrition at the University of California, Berkeley, and a lead author of the study. “GLP-1 works almost perfectly with the first one, so we considered the second one.”
TOFA helped burn fat while preserving muscle
The researchers focused on TOFA, a molecule with an unusual combination of effects on metabolism.
TOFA interferes with the production of lipids, a broad category of fatty substances that includes cholesterol and triglycerides. Lipids perform important functions in the body, but excessive levels of some of them can contribute to metabolic disorders and cardiovascular disease.
At the same time, TOFA activates genes involved in taking up and burning fat for energy. This allows the compound to affect both how the body produces fat and how it uses fat as fuel.
In experiments on mice, TOFA improved insulin sensitivity. Insulin helps move glucose from the bloodstream into cells, so better insulin sensitivity makes it easier for the body to control blood sugar. The compound also lowered triglyceride levels and improved features of fatty liver disease, a condition in which excess fat accumulates in liver cells and can eventually impair liver function.
Obese mice treated with TOFA lost weight primarily through a reduction in body fat, without significant reductions in lean muscle mass. Preserving muscle may be important for strength, mobility and long-term metabolic health.
How TOFA increased energy expenditure
TOFA was first discovered in the 1970s, but the new research identified additional properties that could be relevant to metabolic disease.
The compound belongs to a group known as ACC inhibitors. These compounds interfere with enzymes involved in fatty-acid production, slowing the creation of certain fats.
Other ACC inhibitors have reached mid-stage clinical trials, but none have been approved to treat metabolic diseases. One challenge has been the emergence of unexpected side effects. Many of these compounds can increase blood triglyceride levels, potentially raising the risk of heart disease.
The Berkeley team found that TOFA does more than inhibit ACC. It also activates two cellular receptors, PPARα and PPARδ, which regulate genes involved in fat metabolism.
These receptors act as molecular switches. When activated, they stimulate processes that allow cells to absorb and break down fatty acids to produce energy. In effect, TOFA reduces the production of certain fats while increasing the burning of fats already available to the body.
In mice, this activity increased energy expenditure by as much as 18% without additional physical activity or a rise in body temperature. Unlike other ACC inhibitors, TOFA did not increase triglyceride levels, potentially because of its additional effects on fat metabolism.
“TOFA appears to trigger a coordinated metabolic response,” said Justin Y. Lee, a postdoctoral fellow at the University of California, San Francisco, who conducted the research as a Ph.D. student at Berkeley and was a lead author of the study. “It doesn’t just block lipid synthesis; it also activates energy-consuming pathways and may help the body process excess lipids and glucose more effectively.”
To determine whether the same effects could be reproduced with separate treatments, the researchers gave mice a combination of two compounds: one that blocked lipid production and another that stimulated energy expenditure.
That combination was less effective than TOFA alone at improving overall metabolic health. The result suggests that TOFA’s ability to affect multiple metabolic processes through one molecule may be an important part of its activity.
Potential combination with Ozempic and Wegovy
The researchers also tested whether TOFA could improve the effects of existing GLP-1 treatments.
They combined TOFA with semaglutide, the active ingredient in Ozempic and Wegovy, and with tirzepatide, which is sold as Mounjaro and Zepbound.
Semaglutide and tirzepatide primarily promote weight loss by reducing appetite and food intake. TOFA acts on the other side of the energy-balance equation by increasing the amount of energy the body expends.
In mice, combining TOFA with either drug produced better results than either treatment alone. The combinations significantly improved body weight, blood sugar regulation, insulin levels and triglycerides.
The findings suggest that treatments aimed at reducing calorie intake and treatments that increase energy expenditure could work together to produce stronger metabolic effects.
“In our combination experiments, TOFA acted additively or synergistically with GLP-1 appetite suppressants, so we consider them complementary rather than substitutes,” Naar said.
Researchers therefore do not necessarily envision TOFA replacing drugs such as Ozempic or Wegovy. Instead, it could eventually be developed as an additional treatment that addresses obesity and related metabolic conditions through a different biological mechanism.
Human studies are still needed
Despite the encouraging results, TOFA remains an experimental compound. The findings so far come from animal studies, and its safety and effectiveness in humans have not been established.
Further research will be needed to determine whether the metabolic improvements seen in mice can be reproduced in people and whether TOFA offers meaningful advantages over existing treatments.
To support potential clinical development, Berkeley scientists have formed a biotechnology company called ReRx Therapeutics. The effort is supported by the university’s Life Sciences Entrepreneurship Network, including Nucleate and Berkeley SkyDeck.
If the results can eventually be translated to humans, TOFA could become an addition to treatments for obesity and diabetes. Its potential value lies in encouraging the body to use more energy while helping preserve muscle, rather than relying only on appetite suppression.
The study was funded through discretionary resources provided by the University of California, Berkeley, with additional support from the University of California, San Francisco Liver Center and the University of Michigan Animal Phenotyping Core.
Other authors listed were Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang and Kook Son of Berkeley; Gracia Bonilla, Kashish Chetar and Ruslan I. Sadlev of Massachusetts General Hospital; Kosuke Watari and Michael Karin of the University of California, San Diego; Christina Papa and Bilal N. Shaikh of the Munich Helmholtz Center; and Prabha Ibrahim of ReRx Therapeutics.
Source: www.sciencedaily.com


